



**Aspira Pathlab & Diagnostics Limited**

**Regd. Office:** Flat No. 2, R D Shah Building, Shraddhanand Road, Opp. Railway Station, Ghatkopar (W), Mumbai 400 086  
CIN : L85100MH1973PLC289209

**Date: February 13, 2024**

To,  
Corporate Relations Department  
**BSE Limited,**  
Phiroze Jeejeebhoy Towers,  
Dalal Street, Mumbai-400001.

**Security Code: 540788**

**Security ID: ASPIRA**

**Sub: Outcome of Board Meeting for quarterly financial results**

**Ref: Regulation 30 & 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015**

Dear Sir/Madam,

In continuation to our earlier letter dated February 05, 2024, we wish to inform that the board of directors ("Board") of the Company at their meeting held today i.e. February 13, 2024, inter-alia, have approved unaudited standalone financial results ("Financial Results") of the Company for quarter ended December 31, 2023, based on the recommendation of Audit Committee.

Further, the Board members in their meeting has authorised Mr. Nikunj Mange, Executive Director (DIN: 08489442) of the Company for signing unaudited financial results, enclosed Board Resolution as Annexure

Financial Results together alongwith limited review reports issued by M/s. P Khetan & Co., Chartered Accountants, statutory auditors of the Company are enclosed as Annexure.

The Board Meeting commenced at 03.30 P.M (IST) and concluded at 04.55 P.M.(IST)

The disclosures will also be hosted on Company's website viz [www.aspiradiagnostics.com](http://www.aspiradiagnostics.com)

Kindly take the same on your record.

Thanking you.

Yours Faithfully,

For **Aspira Pathlab & Diagnostics Limited**

---

**Krupali Shah**  
**Company Secretary & Compliance Officer**  
**Enclosure: As above**



**Aspira Pathlab & Diagnostics Limited**

**Regd. Office:** Flat No. 2, R D Shah Building, Shraddhanand Road, Opp. Railway Station, Ghatkopar (W), Mumbai 400 086  
CIN : L85100MH1973PLC289209

**CERTIFIED TRUE COPY OF THE RESOLUTION PASSED BY THE BOARD OF DIRECTORS OF ASPIRA PATHLAB & DIAGNOSTICS LIMITED ("THE COMPANY") IN ITS MEETING HELD ON TUESDAY, FEBRUARY 13, 2024 COMMENCED AT 03:30 P.M (IST) AT UNIT 6 & 7, GROUND FLOOR, BHAVESHWAR ARCADE PREMISES CO-OP. SOCIETY LTD, NITYANAND NAGAR, GHATKOPAR WEST, MUMBAI, MAHARASHTRA 400086.**

**AUTHORISATION FOR SIGNING THE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED DECEMBER 31, 2023.**

**"RESOLVED THAT** pursuant to regulation 33(2)(a) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the unaudited financial results for the quarter and nine months ended December 31, 2023 be and is hereby approved.

**RESOLVED FURTHER THAT** pursuant to regulation 33(2)(b) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Mr. Nikunj Mange, Executive Director (DIN: 08489442) of the Company be and is hereby authorised on behalf of the Board members to sign the aforesaid unaudited financial results for the quarter and nine months ended December 31,2023".

**For and on behalf of  
Aspira Pathlab & Diagnostics Limited**

**Krupali Shah  
Company Secretary & Compliance Officer**



Independent Auditor's Review Report on unaudited quarterly and year to date financial results of Aspira Pathlab & Diagnostics Limited pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

Review Report  
To The Board of Directors  
Aspira Pathlab & Diagnostics Limited

We have reviewed the accompanying statement of **Unaudited Financial Results of Aspira Pathlab & Diagnostics Limited** ("the Company") for the quarter ended December 31, 2023 and for the year to date period from April 1, 2023 to December 31, 2023 ("the Statement") being submitted by the Company pursuant to the requirement of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("SEBI LODR Regulation") including relevant circulars issued by the SEBI from time to time.

This Statement, which is the responsibility of the Company's Management and approved by the Board of Directors of the Company, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under section 133 of the Companies Act, 2013 ("the Act") read with relevant rules issued thereunder and other recognized accounting principles generally accepted in India and in compliance with the Regulations. Our responsibility is to express a conclusion on the Statement based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the statement is free of material misstatement. A review consist of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Act, and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

Based on our review conducted as stated above, nothing has come to our attention that causes us to believe that the accompanying Statement prepared in accordance with the recognition and measurement principles laid down in Ind AS 34, prescribed under section 133 of the Act read with relevant rules issued thereunder and other recognized accounting principles generally accepted in India has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI LODR Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For P Khetan & Co  
Chartered Accountant  
Firm Reg. No. 327386E

*Pankaj Khetan*

Pankaj Kumar Khetan  
Partner

Membership No.- 066080

UDIN: 24066080BKUEAR3208





**ASPIRA PATHLAB & DIAGNOSTICS LIMITED**

(CIN L8510CMH1973PLC289209)

Reg. Office : Flat No. 2, R.D. Shah Bldg., Shradhdhanand Road, Opp. Railway Station, Ghatkopar ( W), Mumbai -400086

Tel No. 022-71975756, Email :support@aspiradiagnostics.com, Website: www.aspiradiagnostics.com

**Unaudited Financial Results for the Quarter and Nine months ended 31st December, 2023**

(Rupees in Lakhs except as stated)

Particulars	Quarter ended			Nine Months ended		Year ended
	31-Dec-23 (Unaudited)	30-Sep-23 (Unaudited)	31-Dec-22 (Unaudited)	31-Dec-23 (Unaudited)	31-Dec-22 (Unaudited)	31-Mar-23 (Audited)
<b>1. Income</b>						
(a) Revenue from Operations						
Sales/Income from Operations	346.17	332.15	437.34	938.70	1,104.92	1,445.69
(b) Other Income	10.04	14.44	11.56	34.51	24.74	32.09
<b>Total income</b>	<b>356.21</b>	<b>346.59</b>	<b>448.91</b>	<b>973.21</b>	<b>1,129.67</b>	<b>1,477.78</b>
<b>2. Expenses</b>						
(a) Cost of Materials consumed	72.72	66.79	69.47	190.74	192.03	249.71
(b) Laboratory Testing Charges	21.06	19.31	12.32	52.94	37.18	51.12
(c) Employee benefits expense	162.10	163.02	152.22	456.16	419.59	559.28
(d) Finance Costs	8.87	9.66	10.32	28.31	32.13	41.72
(e) Depreciation and amortisation expense	38.13	39.00	38.85	116.29	120.78	158.56
(f) Other expenses	127.52	119.90	121.65	345.65	310.89	426.25
<b>Total Expenses</b>	<b>430.40</b>	<b>417.67</b>	<b>404.83</b>	<b>1,190.08</b>	<b>1,112.60</b>	<b>1,486.65</b>
<b>3. Profit / (Loss) before exceptional Items and tax (1-2)</b>	<b>(74.19)</b>	<b>(71.09)</b>	<b>44.08</b>	<b>(216.87)</b>	<b>17.07</b>	<b>(8.87)</b>
4. Exceptional Items	-	-	-	-	-	-
<b>5. Profit / (Loss) before tax (3+4)</b>	<b>(74.19)</b>	<b>(71.09)</b>	<b>44.08</b>	<b>(216.87)</b>	<b>17.07</b>	<b>(8.87)</b>
6. Tax Expenses	-	-	-	-	-	-
<b>7. Profit / (Loss) after tax (5-6)</b>	<b>(74.19)</b>	<b>(71.09)</b>	<b>44.08</b>	<b>(216.87)</b>	<b>17.07</b>	<b>(8.87)</b>
8. Other Comprehensive income (net of tax)	-	-	-	-	-	4.96
<b>9. Total Comprehensive income (7+8)</b>	<b>(74.19)</b>	<b>(71.09)</b>	<b>44.08</b>	<b>(216.87)</b>	<b>17.07</b>	<b>(3.91)</b>
10. Paid up Equity share capital (face value of Rs.10 each)	1,029.30	1,029.30	1,029.30	1,029.30	1,029.30	1,029.30
11. Other Equity	-	-	-	-	-	245.74
<b>12. Earning per share (in Rupees)</b>						
(a) Basic	(0.72)	(0.69)	0.43	(2.11)	0.17	(0.09)
(b) Diluted	(0.72)	(0.69)	0.43	(2.11)	0.17	(0.09)

**Notes:**

1. The above unaudited financial results of the Company for the quarter and nine months ended December 31, 2023 have been reviewed and recommended by the Audit Committee and thereafter approved by the Board of Directors at its meeting held on 13th February, 2024.

2. The above unaudited financial results for the quarter and nine month ended December 31, 2023 has been subjected to limited review by statutory auditors of the Company as required under regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended and not subjected to audit. The auditors have expressed an unmodified opinion in the limited review report for the quarter and nine months ended December 31, 2023.

3. These unaudited financial results of the Company have been prepared in accordance with Indian Accounting standards (Ind AS) prescribed under Section 133 of the Companies Act 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India, to the extent applicable.

4. The Board of Directors of the Company, which has been identified as being the chief operating decision maker, evaluates the Company's performance allocates resources based on the analysis of the various performance indicators of the Company as a single unit. Therefore, there is no reportable segment of the Company in accordance with requirement of Ind AS 108 - Operating Segment, notified under the Companies (Indian Accounting Standard) Rules, 2015.

5. The Code on Social Security, 2020 ('Code') relating to employee benefits during employment and post-employment benefits received Presidential assent in September 2020. The Code has been published in the Gazette of India. However, the date on which the Code will come into effect has not been notified. The Company will assess the impact of the Code when it comes into effect and will record any related impact after the Code becomes effective.

6. The previous period figures have been regrouped/rearrange/reclassified wherever necessary,

FOR ASPIRA PATHLAB & DIAGNOSTICS LIMITED

Nikunj Mange  
Executive Director  
DIN: 08489442  
Place: Mumbai  
Date: 13.02.2024

